RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 No Change in Thrombotic Risk with Short-Term DAPT after Stenting
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 19
SP 21
OP 21
DO 10.1177/155989771319007
UL http://mdc.sagepub.com/content/13/19/21.abstract
AB This article presents the final results from the Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice trial [OPTIMIZE; Feres F et al. JAMA 2013], demonstrating that in patients with coronary heart disease who received a drug-eluting stent (DES), cessation of dual antiplatelet therapy 3 or 12 months after implantation did not increase their risk of the composite endpoint of death, myocardial infarction, stroke or major bleeding, or stent thrombosis at 1-year follow-up.